反应详情

The title compound was obtained following procedure described for example 94, step b), but starting from 4-(4-{5-[(6-oxo-3-pyridin-4-ylpyridazin-1(6H)-yl)methyl]-1H-indazol-3-yl}-1H-1,2,3-triazol-1-yl)benzoic acid (65 mg; 0.12 mmol; 1.0 eq.) and morpholine (4 mL; 46 mmol; 372 eq.) to give the title compound as a white solid. 1H NMR (300 MHz, DMSO-d6) δ 13.42 (s, 1H), 9.38 (s, 1H), 8.70 (dd, J=1.6, 4.6 Hz, 2H), 8.50 (s, 1H), 8.16 (d, J=6.0 Hz, 1H), 8.14 (d, J=3.0 Hz, 1H), 7.92 (dd, J=1.6, 4.6 Hz, 2H), 7.69 (d, J=8.6 Hz, 2H), 7.61 (d, J=8.7 Hz, 1H), 7.54 (d, J=8.7 Hz, 1H), 7.17 (d, J=9.8 Hz, 1H), 5.53 (s, 2H), 3.64 (s, 8H). HPLC (Condition A): Rt 2.24 min (purity 98.8%). MS (ESI+): 560.3, MS (ESI−): 558.2.